Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Vaksin Merah Putih as Heterologous Booster
NCT05918939Phase 1Unknown
- Sponsor
- Dr. Soetomo General Hospital
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of INAVAC in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Dr. Soetomo General Hospital. Primary endpoint: Humoral Immunogenicity Profile - Neutralizing Antibody at 28 days. Status: unknown.
02
Drugs
INAVAC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05918939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918939.